Research
Hormonal
Tirzepatide has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.
Tirzepatide may be a more effective option for managing HbA1c and body weight in patients compared to existing therapies.
StrongSupportsmedium confidence
Tirzepatide, a novel long-acting glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 (GIP/GLP-1) receptor agonist (GIP/GLP-1 RA), has shown greater clinical efficacy in reducing HbA1c and body weight compared with placebo or selective GLP-1 RAs.
Why this rating
Based on the randomized, placebo-controlled study design.
Source
A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
Filip K. Knop et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15875
rct · n=34Cited 35×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →